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Abstract
Purpose The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a commonly used outcome meas-
ure for osteoarthritis. There are different versions of the WOMAC (Likert, visual analogue or numeric scales). A previous 
review of trials published before 2010 found poor reporting and inconsistency in how the WOMAC was used. This review 
explores whether these problems persist.
Methods This systematic review included randomised trials of hip and/or knee osteoarthritis published in 2016 that used 
the WOMAC. Data were extracted on the version used, score range, analysis and results of the WOMAC, and whether these 
details were clearly reported.
Results This review included 62 trials and 41 reported the WOMAC total score. The version used and item range for the 
WOMAC total score were unclear in 44% (n = 18/41) and 24% (n = 10/41) of trials, respectively. The smallest total score 
range was 0–10 (calculated by averaging 24 items scored 0–10); the largest was 0–2400 (calculated by summing 24 items 
scored 0–100). All trials reported the statistical analysis methods but only 29% reported the between-group mean difference 
and 95% confidence interval.
Conclusion Details on the use and scoring of the WOMAC were often not reported. We recommend that trials report the 
version of the WOMAC and the score range used. The between-group treatment effect and corresponding confidence inter-
val should be reported. If all the items of the WOMAC are collected, the total score and individual subscale scores should 
be presented. Better reporting would facilitate the interpretation, comparison and synthesis of the WOMAC score in trials.
Keywords WOMAC · Osteoarthritis · Randomised trial · Reporting
Introduction
A lack of clarity and transparency in how outcome measure-
ment tools are used in clinical research can make it difficult 
to interpret study results [1, 2]. It can be hard to decipher 
whether a clinically meaningful effect has occurred when 
it is unclear how the outcome scores have been calculated. 
Additionally, inconsistency in how an outcome measure is 
used can make it more difficult to compare the results with 
previous research findings. A systematic review published 
in 2012 identified issues of inconsistency and poor reporting 
of the methods and results of the WOMAC measure in knee 
osteoarthritis trials, including poor reporting of the type of 
scale used and how the WOMAC measure was administered 
[3].
The Western Ontario and McMaster Universities Arthri-
tis Index (WOMAC) is a patient-reported outcome meas-
ure for the assessment of lower limb osteoarthritis [4]. The 
WOMAC measure has been used for decades [5–7] and is 
one of the most commonly used outcome measures in hip 
and knee osteoarthritis research [8–10]. The WOMAC meas-
ure has been used in clinical trials to evaluate the efficacy 
of surgical treatments [11, 12], medicinal and biological 
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products [13, 14], devices [15] and physical therapies [16]. 
The WOMAC has been recommended as a trial endpoint 
by the Food and Drug Administration (FDA) [13] and is 
noted as a potential measure for efficacy in recommenda-
tions for updates of FDA and European Medicines Agency 
(EMA) guidance [17–19] and other working groups [20, 21]. 
In addition, the WOMAC has been recommended as one of 
the highest-performing outcome measures for knee and hip 
osteoarthritis, in terms of reliability, validity, responsiveness 
and interpretability [22–24]. The WOMAC is often used as 
a comparator to assess the measurement properties of other 
outcome measures [25, 26]. However, there is variation in 
how the WOMAC outcome score is collected and calculated.
The WOMAC is composed of 24 items over 3 subscales 
(5 for pain, 2 for stiffness and 17 for physical function). Par-
ticipants rate their difficulty for each item, for example, their 
pain level going up and down stairs or their difficulty rising 
from a chair. The seminal paper did not provide the wording 
for the individual questions used in the questionnaire. A user 
guide for the WOMAC is not freely available. The user guide 
includes information on how the WOMAC was derived, 
calculation of scores and specific clinimetric and statistical 
issues. To obtain the user guide, users (researchers or clini-
cians) are required to submit a request to the developer of the 
WOMAC via the website http://www.womac .org, including 
their personal details and information on the intended use of 
the WOMAC measure [27]. As well as being translated into 
over 90 languages, different versions of the WOMAC meas-
ure exist [28]. Items can be rated on a five-level Likert scale 
(no difficulty to extremely difficult) or using a 0–100 mm 
visual analogue scale (VAS) or an 11-point numerical rating 
scale (NRS from 0 to 10). These different approaches mean 
that the range of the WOMAC scores can be unclear if it is 
not explicitly stated [3]. There are also variations in how 
item scores are combined, for example, using the total or 
average of the items. The effect on the total score range of 
the different options for scoring and combining individual 
items of the WOMAC is shown in Table 1.
A lack of clarity in the use and scoring of the WOMAC, 
including the version used and the score range, can hinder 
the interpretation of study results. It is difficult to interpret 
the importance of a 10 point difference between the treatment 
groups when it is unclear whether this relates to a score range 
of 0–96 or 0–2400. This also causes problems when combin-
ing and comparing results across different trials if it is unclear 
whether trials have measured and combined the items of the 
WOMAC differently.
The statistical analysis methods used and how the trial 
results are reported can also make it more difficult to compare 
and synthesise results across different trials. The use of dif-
ferent techniques, dichotomisation of continuous measures, 
adjusting for different covariates or how missing data are han-
dled can impact on the overall treatment effect. Therefore, it is 
important to be transparent in the methodology used to analyse 
trial outcomes. Poor reporting of the results of the analysis 
can also make it more difficult to interpret the trial results. 
For example, reporting only the p value from the analysis and 
omitting the between-group mean difference mean that the 
reader cannot assess the clinical significance of the treatment 
effect on the original scale of the outcome measure.
The previous review that found poor reporting on how 
the WOMAC was used included trials of physical therapies 
published prior to 2010 [3]. Since then, there have been con-
siderable efforts to improve the reporting of clinical trials 
[29]. To our knowledge, no previous review has examined 
the use and scoring of all of the WOMAC subscales (includ-
ing pain, stiffness and function) or the statistical analysis of 
the WOMAC measure.
This review aims to examine the clarity and consistency 
of the scoring, analysis and reporting of the WOMAC meas-
ure and its subscales in two-arm randomised trials of hip 
and/or knee osteoarthritis published in 2016.
Methods
Identification of studies
This review utilised a systematic review which identified a 
cohort of osteoarthritis trials published in 2016 [30].
In the previous review, the cohort of trials were identified 
by searching seven databases for clinical trials of osteoar-
thritis from inception to 31 March 2017: Medline, Cochrane 
Central Register of Controlled Trials (CENTRAL), CINAHL, 
EMBASE, AMED, PsycINFO and PEDro. Searches were 
limited to trials published in 2016. An example of the search 
strategy developed for the previous review of osteoarthritis 
trials is given in Online Resource 1 [30].
Selection of studies
Eligibility criteria for the cohort of trials
The cohort of trials included in the previous review were 
two-arm parallel-group randomised controlled trials in a 
sample of people living with hip and/or knee osteoarthritis 
Table 1  Score range for the WOMAC measure using different ver-
sions and methods to combine 24 individual item scores
Combine 24 item scores using
Total Average Percentage
Version used for item scores
 Likert scale (item 0–4) 0–96 0–4 0–100
 NRS (item 0–10) 0–240 0–10 0–100
 VAS (item 0–100) 0–2400 0–100 0–100
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published in 2016. The cohort did not include pilot or fea-
sibility studies, since the main outcomes could relate to, for 
example, feasibility of recruitment, rather than measuring 
the efficacy of the intervention.
Additional screening criteria
We restricted the eligibility to include only those trials that 
measured the WOMAC or one of its subscales (pain, stiff-
ness or physical function) as a trial outcome, whether pri-
mary or secondary. Trials that only measured the WOMAC 
at baseline were excluded since we expected these trials to 
report fewer details on the use of the WOMAC when it was 
not used as a trial outcome to measure treatment efficacy. 
Eligibility screening was conducted independently by pairs 
of reviewers.
Data extraction
Data extraction on study characteristics included the study 
design, population, sample size and follow-up assessment 
time points. To further describe the trial samples, data were 
extracted on the baseline demographics for the WOMAC 
(e.g. mean score) and whether the WOMAC was used to 
restrict eligibility to participate in the trial.
For the WOMAC measure and its subscales, data were 
extracted on the version of the WOMAC used (VAS, NRS 
or Likert scale) and the scoring system (range of individual 
items and overall scale or subscale). It was noted when these 
details were unclear or not reported.
Data on the statistical methods used to analyse the 
WOMAC, including covariate adjustment and dichotomi-
sation of the WOMAC score, were also extracted and sum-
marised. This would impact the effect estimates reported 
for the WOMAC score. Summarising this information on 
the analysis of the WOMAC will allow future trials to uti-
lise consistent methodology to facilitate the comparison of 
trials results. Data were extracted on how trials examined 
the impact of missing data on the WOMAC to explore the 
likelihood of bias in the treatment effects.
Finally, data were extracted on how the results of the 
WOMAC measure were reported, for example, whether and 
how the within-group WOMAC scores and the between-
group treatment effect were presented. The reporting of the 
results of the WOMAC will influence the ease with which 
trial results can be interpreted, compared and combined 
together.
Data synthesis
Categorical data were summarised using the number and 
proportion within each category. For continuous outcomes, 
data were summarised using the median and interquartile 
range. Data were summarised separately for the WOMAC 
total score and each individual subscale.
Results
Characteristics of included studies
The original cohort of trials included 116 studies, which were 
two-arm randomised trials of hip and/or knee osteoarthritis 
(Fig. 1). Of these 116 trials, 62 reported using the WOMAC 
as an outcome measure and were included in this review. The 
majority of the included trials were single-centre, superior-
ity trials of knee osteoarthritis (Table 2). The median sam-
ple size was 75 randomised participants (IQR 50–148). The 
smallest trial randomised 20 participants and the largest ran-
domised 606 participants. The median follow-up period was 
4.5 months (IQR 1.5–6). Some trials assessed participants 
only immediately after a single session of an intervention. 
The maximum length of the follow-up period was 3 years.
The WOMAC total score was reported in 41 trials (66%, 
n = 41/62) and it was used as the primary outcome in 22% 
of these trials (n = 9/41) (Fig. 2). The pain and function sub-
scales were reported in 39 trials (63%, n = 39/62). However, 
only 30 trials reported the stiffness subscale (48%, n = 30/62). 
Of the 41 trials reporting the WOMAC total score, less than 
half reported the results for all three individual subscales 
(pain, stiffness and function) (37%, n = 15/41) (Table 3).
Few trials restricted eligibility of the trial participants 
using the WOMAC measure (6%, n = 4/62). For example, 
one trial only included participants > 300 on a 0–500 scale 
for the WOMAC pain subscale.
An alternative version of the WOMAC was used in 12 
trials, most commonly using a translated version (n = 8), a 
shortened version with reduced items or combining only two 
subscales (n = 3) or alternative item weightings (n = 1). None 
of the trials made the WOMAC questionnaire available or 
provided details of the wording of individual items as part 
of the results publication. Of the 10 trials that referred to a 
published protocol, one trial provided the WOMAC ques-
tionnaire used as an appendix to the study protocol [31].
Scoring of the WOMAC
The version of the WOMAC most commonly used was 
5-point Likert scale with a range of 0–96 (41%, n = 17/41) 
(Table 4). The smallest range used was 0–10 and the largest 
range used was 0–2400.
In most trials, the range for the total score was not 
reported and it was unclear how the individual items were 
combined. The range of the total score was often assumed 
from the mean score or range of a single item; however, it 
was still unclear for 20% of trials (n = 8/41).
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For the individual WOMAC subscales, the scoring ver-
sion and item range were reported more clearly than for the 
WOMAC total score. For example, the scoring version was 
unclear for 44% of trials reporting the WOMAC total score 
(n = 18/41), compared to 21% reporting the pain subscale 
(n = 8/39). Around ¾ of trials reported the version used 
and item range for each subscale (Online Resource 2). The 
range for the subscale was apparent for all trials; half of tri-
als reported the range and for the other half, the range could 
be assumed based on the mean score or the item range.
In the trial results, four trials dichotomised participants 
based on the WOMAC total score (n = 2) or WOMAC pain 
score (n = 2) and none used the same cut-off points. Two 
additional studies categorised participants as ‘treatment 
responders’ using a combination of the WOMAC post-treat-
ment score, WOMAC change score and the patient global 
assessment score according to the OARSI criteria [32]. No 
studies reported the WOMAC as a subset of the items from 
the KOOS score.
Trials reported that the WOMAC was completed by the 
participant (34%, n = 21/62) or by the participant with a cli-
nician assessor (34%, n = 21/62). The data collection for the 
WOMAC was unclear for the remaining 20 studies (32%, 
n = 20/62). No trial reported that the WOMAC was collected 
by proxy for the participant. When an outcome assessor was 
involved, it was often unclear whether the participant com-
pleted a written version of the WOMAC questionnaire that 
was checked by the assessor or whether the assessor delivered 
the questionnaire verbally. One trial noted that ‘the question-
naire was read by the investigator for illiterate patients’ [33].
Analysing the WOMAC
To analyse the WOMAC measure, the most commonly 
used methods were a t test, repeated-measures ANOVA or 
a mixed effects model (Table 5). The majority of trials used 
complete case analysis (24%, n = 10/41) and few trials used 
multiple imputation to assess the impact of missing data 
(7%, n = 3/41). Statistical analysis methods and handling of 
Fig. 1  Flow of studies Records identified through 
database search (n = 4091)
Records after duplicates removed 
(n = 2955)
Records screened by title and 
abstract (n = 2955)
Abstracts excluded (n=2611)
Animal or tissue study: n=90
Systematic review: n=231
Other review: n=443
Non-randomised study: n=1155
Qualitative study: n=22
Study protocol: n=62
Erratum: n=3
Not treatment effectiveness: n=8
Not OA: n=249
Mixed population (OA and other): n=16
Prevention of OA: n=5
Not only hip/knee OA: n=87
Pilot, feasibility or exploratory study: n=36
Factorial or crossover design: n=1
More than two study arms: n=1
Conference abstract: n=97
Secondary analysis: n=94
Duplicate publication of same study: n=11
Full-text articles 
assessed for eligibility 
(n = 344)
Full-text articles excluded (n = 228)
Tissue study: n=1
Other review: n=22
Non-randomised study: n=32
Study protocol: n=1
Not treatment effectiveness: n=2
Not OA: n=3
Mixed population (OA and other): n=24
Prevention of OA: n=1
Not only hip/knee OA: n=5
Pilot, feasibility or exploratory study: n=20
Factorial or crossover design: n=7
More than two study arms: n=35
Duplicate publication of same study: n=2
Conference abstract: n=18
Secondary analysis: n=23
Non-English language: n=13
Publication year: n=18
Full text not accessible: n=1
Eligible trials 
(n = 116)
WOMAC measure 
was a trial outcome 
(n = 62)
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missing data was similar for the WOMAC total score and 
the individual subscales.
For the WOMAC total score, around ¼ of trials reported 
using covariate adjustment in the analysis (27%, n = 11/41). 
Covariate adjustment was more common for analysis on the 
individual WOMAC subscales (46% for the pain subscale, 
n = 18/39). For adjusted analyses, trials most commonly 
adjusted for baseline score (13 trials), BMI (7 trials), sex (6 
trials) and age (5 trials).
Interpreting results from the WOMAC
The majority of studies reported the within-group mean 
post-treatment score (88%, n = 36/41 for WOMAC total) 
and the corresponding standard deviation (68%, n = 28/41 
for WOMAC total) (Table 6). For the WOMAC total, the 
between-group mean difference with the corresponding 95% 
confidence interval was reported in less than 1/3 of trials (29%, 
n = 12/41). The proportion of studies reporting the between-
group difference was higher for the WOMAC subscales but 
still remained below half (46%, n = 18/39 for the pain and 
function subscales). For the majority of trials, the results of 
the between-group analyses were reported using only the p 
value (49%, n = 20/41).
Of the 4 trials where dichotomisation of the WOMAC score 
was used, all reported the proportion of participants achieving 
the cut-off score, one reported the odds ratio and two reported 
the corresponding p value.
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Fig. 2  Use of WOMAC total and subscales as a trial outcome meas-
ure (n = 62) (Number of trials shown in graph bars, percentage of tri-
als shown on y-axis)
Table 3  Reporting of WOMAC total and individual subscales 
(n = 62)
a For one study, the total score used was the sum of the pain and func-
tion subscales only. For three studies, the stiffness subscale was used 
to calculate the total score but results on the stiffness subscale were 
not reported separately
b One study reported pain subscale only and one study reported the 
function subscale only
n (%)
Reported total score 41 (66)
    Total and all three subscales 15 (24)
    Total and two subscales (pain and function) 4 (6)a
    Total only 22 (35)
Did not report total score 21 (34)
    Three individual subscales 15 (24)
    Two subscales (pain and function) 4 (6)
    One subscale 2 (3)b
Table 2  Characteristics of included studies (n = 62)
n %
Study design
 Individually randomised 61 98
 Cluster-randomised 1 2
Study hypothesis
 Superiority 40 65
 Non-inferiority 3 5
 Multiple 1 2
 Unclear 18 29
Allocation ratio
 1:1 61 98
 Unclear 1 2
Study centres
 Single centre 46 74
 Multi-centre 9 15
 Unclear 7 11
Funding source
 Industry 8 13
 Non-industry 25 40
 Combination 3 5
 No funding 4 6
 Not reported 22 35
Population
 Knee OA 57 92
 Hip OA 4 6
 Hip or knee OA 1 2
Intervention
 Drug 19 31
 Surgery 4 6
 Exercise 14 23
 Other 25 40
Comparator
 Active treatment 41 66
 Usual care 8 13
 Placebo or sham 13 21
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Discussion
Summary of findings
The WOMAC is a commonly used outcome measure in trials 
of hip and knee osteoarthritis. It was used to assess self-
reported patient outcomes in around half of hip and knee 
osteoarthritis trials, predominantly as a secondary outcome 
measure. However, there was substantial variation in the 
way the WOMAC measure was implemented and analysed. 
The scoring range for the WOMAC total score was 0–96 for 
most trials; however, it was as small as 0–10 for some trials 
and as large as 0–2400 for others. Randomised trials often 
did not adequately report the version of the WOMAC used, 
how individual item scores were combined and the range 
of the score.
Most studies used a t test, repeated-measures ANOVA 
or mixed effects model to analyse the WOMAC score. The 
majority of studies did not adjust for baseline covariates in 
their analysis. In the study results, the mean score and vari-
ation within the treatment groups was well reported. How-
ever, interpretation of the results of between-group analy-
ses was hindered by poor reporting, with less than half of 
trials reporting the between-group mean difference for the 
WOMAC score.
Comparison with existing literature
Only one previous review has looked at the use of the 
WOMAC [3]. The results of this review align with and 
build upon the findings of Woolacott et al. Both reviews 
found that the type of scale and the score range were 
Table 5  Analysis of the WOMAC total score (n = 41)
n %
Statistical analysis method
 t test 13 33
 Repeated-measures ANOVA 9 23
 Mixed model 8 20
 ANCOVA 3 8
 Mann–Whitney U test 6 15
 Other: Kruskal–Wallis H test 1 3
Adjusted for covariates
 Yes 11 27
 Unclear 4 10
 No 26 63
Method to handle missing data
 Complete case 10 24
 Multiple imputation 3 7
 Single imputation (e.g. LVCF) 3 7
 Mixed model without imputation 5 12
 No missing data 4 10
 Unclear 16 39
Table 6  Reporting of results for the WOMAC total score (n = 41)
n %
Summary score
 Mean post-treatment score 28 68
 Mean change score 2 5
 Mean post-treatment and change scores 8 20
 Median post-treatment score 1 2
 Multiple reported 1 3
 None reported 1 3
Within-group variation
 Standard deviation 25 61
 95% confidence interval 5 12
 Range 1 2
 Standard deviation and 95% confidence interval 2 5
 Multiple reported 1 2
 None reported 7 17
Between-group score
 Mean difference 13 32
 None reported 28 68
Between-group variation
 95% confidence interval and p value 10 24
 95% confidence interval 3 7
 p value 20 49
 p value interval (e.g. p < 0.05) 6 15
 None reported 2 5
Table 4  Version used and scoring of the WOMAC total (n = 41)
n %
Scoring version
 Likert scale 17 41
 NRS 3 7
 VAS 3 7
 Unclear 18 44
Item range
 0–4 21 51
 0–10 7 17
 0–100 2 5
 1–4 1 2
 Unclear 10 24
Method to combine subscales
 Sum 31 76
 Average 3 7
 Sum and convert to percentage 1 2
 Sum with equal weighting for subscales 1 2
 Unclear 5 12
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unclear for 20% and 10% of trials, respectively, with these 
values being explicitly reported in only around half of tri-
als. Despite the passage of time and increasing awareness 
of, and initiatives to address, the need for improvement in 
the reporting of clinical trials, we found little evidence of 
improvement in reporting on essential characteristics of 
the WOMAC measure. There was also no indication of 
improvement in the consistency across trials on how the 
WOMAC is measured. Additionally, restricting focus to 
a particular clinical condition did not lead to greater con-
sistency being observed. This suggests that the previously 
observed variation in implementation and poor reporting 
is a generic issue, irrespective of the clinical condition.
There were some differences between this review’s 
findings and that of Woolacott and colleagues. In this 
review, most trials reporting the WOMAC pain sub-
scale also reported the function and stiffness subscales, 
whereas the previous review found that the function sub-
scale was rarely reported. It is unclear whether this is due 
to changes over time or the differences of the interven-
tions and clinical area being considered. However, both 
reviews found that many trials report the results using the 
WOMAC total score without reporting the results of the 
component subscales.
Strengths and limitations
This review examines the reporting of the WOMAC in an 
up-to-date sample of trials identified using a systematic 
search strategy. This is the first review to examine the 
reporting of the function and stiffness subscales of the 
WOMAC, as well as the pain subscale and total score. 
This review did not restrict eligibility based on the inter-
vention, including trials of physical therapies, surgery and 
pharmacological treatments.
This review is limited in that it only includes trials 
published during a 1-year period. Therefore, the results 
do not provide information on the trends in the use and 
reporting of the WOMAC over time. It also does not con-
sider the use of the WOMAC in trials of conditions other 
than knee or hip osteoarthritis, such as ankle osteoar-
thritis [34, 35] or rheumatoid arthritis [7]. An additional 
limitation is that the use of the WOMAC may be different 
in observational or multi-arm studies, compared to two-
arm randomised trials.
Implications
This review demonstrates that problems persist in the 
poor reporting and inconsistency in the measurement 
of the WOMAC total score and the WOMAC subscale 
scores. This makes it difficult to interpret trial results and 
hinders comparisons between trials, for instance, where 
the range of the scale is unknown. The clinical importance 
of a 20-point difference between treatments varies greatly 
depending on whether a 0–96 scale or 0–2400 scale was 
used. Poor reporting of the effect estimates from between-
group analyses could also hinder the interpretation of 
study results.
Analysing only the WOMAC total score without examin-
ing the individual subscales may hide intricacies in the study 
results. For example, there may be an improvement in pain 
but worsening function, which would not be evident since 
the total score remains unchanged. The presentation of the 
individual subscale results would be important if the changes 
in specific domains are seen as more desirable than oth-
ers due to patient preference or the hypothesised treatment 
mechanisms [36]. Reporting the results of individual sub-
scales also makes it easier to compare the trial results with 
other trials where only individual subscales are reported 
without the total score.
Future research
Because there are multiple versions of the WOMAC meas-
ure in use, this means that research into the measurement 
properties of the WOMAC can be of uncertain applicability. 
Although the different versions have been shown to be cor-
related, it is unclear whether the psychometric properties are 
similar [37]. When assessing validity and responsiveness, 
the sensitivity of a 0–4 Likert scale, 0–10 NRS and 0–100 
VAS are likely to be different. Future research should com-
pare the different versions of the WOMAC measure, in terms 
of the validity, responsiveness and usability. The findings 
of this research could be used to make recommendations on 
which version of the WOMAC measure is most appropriate 
for particular settings and how it should be measured and 
analysed.
Further studies could also examine whether, or when, it 
is appropriate to ‘translate’ the results from one version of 
the WOMAC into another version. For instance, it is unclear 
whether results for the WOMAC Likert pain subscale (range 
0–20) can be multiplied to translate the results onto the 
WOMAC VAS pain subscale (range 0–500). If it is appro-
priate to standardise different versions of the WOMAC to the 
same scale (e.g. converting all to a 0–100 scale), this would 
make it easier to compare the results of different trials and 
combine results in meta-analyses.
Recommendations for using the WOMAC
When publishing the results of osteoarthritis trials, trialists 
should clearly report the version of the WOMAC measure 
that was used and the associated score range. Unless there is 
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sufficient justification to do otherwise, trialists should favour 
the 5-point Likert scale version and combine scores by sum-
mation of the individual items. Since the Likert scale ver-
sion is the most commonly used, this would make it easier 
to compare the results with the findings of previous trials.
Trialists using the WOMAC total score should also 
report results for the individual subscales for pain, function 
and stiffness. This would allow readers to see whether the 
treatment effect (or lack of it) is consistent across the three 
domains.
Trialists should also assess the robustness of the results 
based on adjustment for baseline covariates and the handling 
of missing data.
Conclusion
While the WOMAC measure is commonly used in trials of 
hip and knee osteoarthritis, there is wide variation on how 
the WOMAC is implemented and analysed. Relevant details 
are often poorly reported and, as such, the ranges of the 
outcome scales are often unclear. This inhibits the interpre-
tation of findings and comparisons with other studies. The 
interpretation of results on the WOMAC measure was also 
hindered by other limitations, such as not using an analysis 
method that estimates an effect size, not reporting an effect 
size estimate or not exploring the effects of assumptions on 
missing data mechanisms.
Trials should report the version of the WOMAC used, 
the score range and how item scores were combined. Future 
research should examine which version of the WOMAC 
measure has optimal properties. Improved consistency and 
transparency in how the WOMAC is measured would make 
it easier to interpret trial results and facilitate the comparison 
of results across trials.
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